Stock Market Impact: Shares of Zealand Pharma A/S fell more than 26% on 8 June 2026 after the company released Phase III trial data showing high discontinuation rates due to gastrointestinal adverse events.
Listed Companies and Sectors: The data pertains to Zealand Pharma (pharmaceuticals) and its partner Boehringer Ingelheim, which holds the global development and commercialization rights for the obesity drug survodutide.
Investment Flows: Wolfe Research maintains an “outperform” rating with a DKK750 price target, implying approximately 130% upside from the pre‑drop close, potentially influencing analyst coverage and investor sentiment.
Interest Rates, Inflation, and Liquidity: No direct references to monetary policy, interest rates, or liquidity in the announcement.
Fiscal or Monetary Policy: No fiscal or monetary policy measures mentioned.
